Ocular melanoma is diagnosed from ultrasonography, fluorescein angiography, enhanced depth imaging optical coherence tomography, and fine-needle aspiration biopsy. Treatment depends on the extent of disease, condition of the eye, spread to distant sites of metastasis. Surgical options include enucleation, orbital exenteration, endoresection, and exoresection. Prompt evaluation for ocular melanoma is essential to prevent metastasis, which leads to a fatal prognosis. This activity will discuss how an interprofessional team can improve outcomes.
Describe the etiology and epidemiology of ocular melanoma.
Review the pathophysiology and histopathology of ocular melanoma.
Outline the evaluation and treatment of ocular melanoma.
Outline the prognosis and complications of ocular melanoma can be improved by utilizing an interprofessional team.
Melanoma is a malignant overproliferation of melanocytes. Ocular melanoma is the second most common type of melanoma after cutaneous and is the most common primary intraocular malignant tumor in adults.
The prognosis of uveal melanoma has remained unchanged over the past few decades. The systemic prognosis depends on the size and other characteristics of the lesion. It is not affected by the choice of local treatment. Ocular melanoma tends to spread hematogenously and often involves the liver.
Common risk factors that have been linked to ocular melanoma include light skin color, atypical cutaneous nevi, light eye color, iris nevi, and freckles. Occupational sun exposure, tanning, and outdoor activities have also been associated with ocular melanoma.
There has also has been a genetic correlation between uveal and cutaneous melanoma at the CLPTM1L locus. Different genetic mutations have been associated with uveal melanoma. There have been studies showing an association of ocular melanoma with mutations in the genes encoding for the G-protein alpha-subunit.
There are no known direct causes of ocular melanoma, though incidence is highest among people with lighter skin and blue eyes. Uveal melanoma affects about 6 to 8 persons per million each year in the western world. Less than 2% of patients show evidence of metastasis at presentation; over 40% of patients will die from widespread disease. The most common ocular melanoma is uveal melanoma. There has been a 30% greater incidence of ocular melanoma in females than males. There has been a higher association in non-Hispanic whites, with an incidence of 6.02 cases per million. Incidences of ocular melanoma are lower in African Americans and Asians, with incidences of 0.31 per million and 0.39 per million respectively.
Oxidative damage done to pigmented tissues, which are controlled by the degree and type of iris pigmentation, is considered to be one of the primary mechanisms by which ocular melanoma develops. Another theory associated with the development of uveal melanoma includes an alteration of the fundamental genetic sequence from abnormal adenine-to-cytosine mutations. Ciliochoroidal melanoma, on the other hand, has been associated with adenine-to-thymine mutations. Melanomas may also arise from de-novo lesions already existing as a pre-nevus lesion.
Melanomas may show the following histological types: spindle cell melanoma (9.0%), mixed cell melanoma (86.0%), and epithelioid cell melanoma (5.0%). When staining cells on pathology, S-100 is the most sensitive for picking up melanocytic lesions. More specific markers for melanoma include HMB-45, tyrosinase, and MART-1/Melan-A.
History and Physical
The ocular melanomas can have a spectrum of symptoms and may depend upon the location of the malignancy. Common symptoms include blurry vision, visual field defect, flashing lights, redness, irritation, pain, and a pressure-like sensation. Choroidal tumors can cause retinal detachment based on the shape of the malignancy. Conjunctival melanomas can present as elevated lesions with increased pigmentation. Ciliary body tumors can cause lens displacement and disturbances in accommodation. Iris melanomas can distort the pupil, cause cataracts, and even cause glaucoma.
The basic evaluation of an eye malignancy includes fundoscopic examination, fundus photography, and ocular ultrasound. Depending on the location of the malignancy, various imaging modalities can be used. If the orbit is involved, CT or MRI is the first step. If lymphatic involvement is suspected, then a PET scan is warranted, along with an MRI of the head and neck. A fine-needle aspiration biopsy of the suspected involved lymph nodes should be performed. Fluorescein angiography (FA) and indocyanine green angiography (ICGA), have been used to help differentiate melanoma from underlying pathology, to assess for secondary neovascularization or ischemia, and to further visualize lesions obscured by media opacity. Optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) have made it possible to non-invasively image superficial and deep structures of the retina and choroid, which provides more detail than a simple clinical exam.
Treatment / Management
Depending on the size of the melanoma, various treatment modalities can be used. For uveal melanoma, options include the following:
Plaque radiation therapy
Particle beam radiotherapy
Gamma knife stereotactic radiosurgery
Local surgical resection
Advances aimed at vision and eye preservation have been made with techniques such as transretinal endoresection and transscleral resection.
Studies show that there may be 0% to 15% response rates from using chemotherapeutic agents as used in cutaneous melanoma. Chemotherapy agents that have been used are dacarbazine, temozolomide, cisplatin, treosulfan, and fotemustine.
Iris melanomas can be usually treated with surgical resection. Larger iris melanomas that are not able to be surgically resected will be treated with plaque therapy or enucleation.
Small and medium-sized choroidal tumors are mostly treated by radiation therapy, while larger advanced tumors are treated by enucleation or orbital exenteration when there is spread into the orbit.
Effective treatment regimens for conjunctival melanoma include local excision with adjuvant chemotherapy (mitomycin).
Clinically, various diseases may present similarly to ocular melanoma. These growths may be able to be differentiated based on clinical appearance. However, biopsy is the only definitive way to confirm a diagnosis.
Choroidal body: Choroidal nevus, choroidal hemangioma, osteoma; hemorrhagic conditions like age-related macular degeneration (AMD) and hemorrhagic choroidal detachment
Brachytherapy involves suturing a plaque to the sclera to deliver focal radiation to the tumor. It is the most frequently employed modality in the United States. Iodine-125 is the preferred isotope in the U.S. and emits gamma radiation, which penetrates deeply into tumors. Following treatment, a regular ophthalmologic examination should be performed to monitor for complications, including radiation-induced retinopathy, cataracts, neovascular glaucoma, and macular edema, which can develop up to 5 years after therapy. The use of intravitreal anti-vascular endothelial growth factor (VEGF) after brachytherapy has been shown to reduce or delay the rate of macular edema and vision loss.
At initial diagnosis, the following tests are performed:
CT abdomen and pelvis with contrast
CT chest with contrast
CT soft tissue neck with contrast
Liver MRI with contrast
When the tumor is removed, the following should be noted:
A missing copy of chromosome 3 (monosomy 3) is seen in about 50% of uveal melanoma: this is associated with a higher risk of the tumor metastasizing. Tests are now available by sending a sample of the tumor for testing. Based on the genetic results and using patient information (age, gender, size of the tumor, histology, etc.), the risk of developing metastases is calculated.
Several clinical and histopathological variables of primary uveal melanoma were found to be associated with metastatic death. These include increasing patient age, increasing tumor size (tumor elevation and independently tumor diameter), ciliary body involvement, extraocular extension, epithelioid cell type, lymphocytic infiltration, presence of fibrovascular loops, and several biomarkers, including human leukocyte antigen (HLA) molecules, and others, by immunohistochemical methods.
Approximately 50% of patients with ocular melanoma will develop metastases by 10 to 15 years after diagnosis. A small percentage of people will develop metastases even later, i.e. 20-25 years after their initial diagnosis. Metastatic disease is universally fatal. This 50% mortality rate is unchanged despite treatment advances in treating the primary eye tumor. More research is needed urgently to improve patient outcomes.
Aside from metastasis and death, complications of ocular melanoma include vision loss, glaucoma, retinal detachment, cataractogenesis, induced astigmatism, and macular edema. Post radiation complications include radiation-induced retinopathy, cataracts, neovascular glaucoma, and macular edema, all of which can develop up to 5 years after therapy.
The following consultations are recommended when ocular melanoma is suspected.
Opthalmology with ocular oncology training
Deterrence and Patient Education
If ocular melanoma is suspected, monitoring for metastasis should be performed regularly with emphasis on compliance with follow-up visits, regardless of stage and treatment. Patients should have dilated fundal examination, liver function test, alkaline phosphatase, LDH, and CT or right upper quadrant ultrasound to assess for liver metastasis. Frequency depends on the stage of the tumor, and those that have a high risk of metastasis should be monitored as frequently as 3-4 months.
The best way to screen for ocular melanoma in the general population is to get regular, complete eye exams.
Enhancing Healthcare Team Outcomes
Ocular melanoma is a serious and lethal clinical malignancy with a poor prognosis when it metastasizes. Close attention needs to be paid attention to when patients present with benign lesions in their uveal tract from their iris to the choroid. An interprofessional team can be helpful for proper assessment and treatment. Ophthalmologists and optometrists are often the first to see the lesion. A complete, dilated eye exam with appropriate imaging should then be performed. Treatment of the ocular disease is performed by an ocular oncologist. Medical and radiation oncologists may be consulted if there is suspected metastasis. Ophthalmic technicians, nurses, and medical assistants are involved in the treatment, monitoring, and team coordination of the patient's care. Oncologic pharmacists review medications, verify doses and check for drug-drug interactions. Pharmacists and nurses help with patient and family education. Close follow-up with repeat imaging directed by the oncologist should be done diligently. An interprofessional approach results in the best outcomes.[Level 5]
(Click Image to Enlarge)
Contributed by Katherine Humphries
Thomsen H,Chattopadhyay S,Hoffmann P,Nöthen MM,Kalirai H,Coupland SE,Jonas JB,Hemminki K,Försti A, Genome-wide study on uveal melanoma patients finds association to DNA repair gene TDP1. Melanoma research. 2019 Oct 11; [PubMed PMID: 31626034]
Histopathologic characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular Melanoma Study. COMS report no. 6. American journal of ophthalmology. 1998 Jun; [PubMed PMID: 9645714]
Jovanovic P,Mihajlovic M,Djordjevic-Jocic J,Vlajkovic S,Cekic S,Stefanovic V, Ocular melanoma: an overview of the current status. International journal of clinical and experimental pathology. 2013; [PubMed PMID: 23826405]